Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Allen Barbie, M.D.

Co-Author

This page shows the publications co-authored by David Barbie and Russell Jenkins.
Connection Strength

4.048
  1. Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. Annu Rev Med. 2018 01 29; 69:333-347.
    View in: PubMed
    Score: 0.733
  2. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.733
  3. Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma. Cancer Discov. 2017 08; 7(8):799-801.
    View in: PubMed
    Score: 0.720
  4. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer. 2015 Sep; 16(5):e101-4.
    View in: PubMed
    Score: 0.607
  5. Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2021 01 19; 131(2).
    View in: PubMed
    Score: 0.229
  6. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 2018 10 09; 18(20):3129-3143.
    View in: PubMed
    Score: 0.196
  7. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018 08; 24(8):1143-1150.
    View in: PubMed
    Score: 0.193
  8. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018 01; 118(1):9-16.
    View in: PubMed
    Score: 0.185
  9. Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunol Res. 2016 06; 4(6):520-30.
    View in: PubMed
    Score: 0.165
  10. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404.
    View in: PubMed
    Score: 0.050
  11. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.049
  12. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
    View in: PubMed
    Score: 0.049
  13. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clin Cancer Res. 2018 10 01; 24(19):4854-4864.
    View in: PubMed
    Score: 0.048
  14. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
    View in: PubMed
    Score: 0.046
  15. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst. 2017 08 23; 5(2):105-118.e9.
    View in: PubMed
    Score: 0.045
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.